PUBLIC COMPANY
save$RAPPRapport Therapeutics, Inc.
$RAPP23.76-4.27%Boston, MA, USupdated 17h ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- phase3Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
- phase2Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder
- phase3Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
- phase2Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy
- phase2A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
🐶 Hiring Signal
Where Rapport Therapeutics, Inc. is staffing up — a leading indicator of pipeline and commercial priorities.
therapeutic areaCNS / Neuroscience 14
News
- Steady stream of crossover rounds stock biotech's IPO pipelineBiotech crossover rounds could top $4.22 billion across about 28 rounds this year, PitchBook forecasts.biospace · 2mo ago
Data sources
last refreshed 57m ago
Found something off?
comments(0)
5-min edit window · permanent after that